These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 28608988)

  • 21. [Pharmacogenomics of vitamin K antagonists].
    Guzmán N; Vega M; Reyes F; Guzmán-Oyarzo D; Andaur M; Boguen R; Letelier P
    Rev Med Chil; 2020 Sep; 148(9):1307-1314. PubMed ID: 33399707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [FREQUENCY OF POLYMORPHISM OF VKORC1 AND CYP2C9 GENES IN TWO REGIONS OF GEORGIA].
    Jokhadze T; Kakauridze N; Buadze T; Gaiozishvili M; Lezhava T
    Georgian Med News; 2016 Jan; (250):46-51. PubMed ID: 26870974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.
    Alrashid MH; Al-Serri A; Alshemmari SH; Koshi P; Al-Bustan SA
    Mol Diagn Ther; 2016 Apr; 20(2):183-90. PubMed ID: 26940072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
    Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
    J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support.
    Awad M; Czer LS; Soliman C; Mirocha J; Ruzza A; Pinzas J; Rihbany K; Chang D; Moriguchi J; Ramzy D; Esmailian F; Kobashigawa J; Arabia F
    ASAIO J; 2015; 61(4):391-6. PubMed ID: 26125664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia.
    Cifuentes RA; Murillo-Rojas J; Avella-Vargas E
    Biomedica; 2016 Mar; 36(1):91-100. PubMed ID: 27622442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.
    Moreau C; Pautas E; Gouin-Thibault I; Golmard JL; Mahé I; Mulot C; Loriot MA; Siguret V
    J Thromb Haemost; 2011 Apr; 9(4):711-8. PubMed ID: 21255252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.
    Varnai R; Sipeky C; Nagy L; Balogh S; Melegh B
    Environ Toxicol Pharmacol; 2017 Dec; 56():282-289. PubMed ID: 29055218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotype-guided coumarin dosing: where are we now and where do we need to go next?
    Baranova EV; Verhoef TI; Asselbergs FW; de Boer A; Maitland-van der Zee AH
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):509-22. PubMed ID: 25595525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration.
    Santos PC; Marcatto LR; Duarte NE; Gadi Soares RA; Cassaro Strunz CM; Scanavacca M; Krieger JE; Pereira AC
    Pharmacogenomics; 2015 Jul; 16(8):865-76. PubMed ID: 26050796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Genetic determinants of response to vitamin K antagonists].
    Mundi S; Distante A; De Caterina R
    G Ital Cardiol (Rome); 2014 Sep; 15(9):482-93. PubMed ID: 25298357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
    Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
    J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Rare Combination of CYP2C9*3/*3 and VKORC1 1639AA in a Patient Who Had Myxoma and Thromboembolism.
    Son KH; Lee SI; Choi CH; Park KY; Park CH
    Ann Thorac Surg; 2020 Apr; 109(4):e283-e284. PubMed ID: 31520636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons learned from the influence of CYP2C9 genotype on warfarin dosing.
    Tidbury N; Preston J; Lip GYH
    Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):185-188. PubMed ID: 37254883
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of 16 genotype-guided Warfarin Dosing Algorithms in 310 Korean Patients Receiving Warfarin Treatment: Poor Prediction Performance in VKORC1 1173C Carriers.
    Yang M; Choi R; Kim JS; On YK; Bang OY; Cho HJ; Lee SY
    Clin Ther; 2016 Dec; 38(12):2666-2674.e1. PubMed ID: 27887741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9*1/*3 and VKORC1-1639G/A genotype.
    Yagishita H; Minami S; Akamine Y; Kato S; Iijima K; Miura M
    J Clin Pharm Ther; 2019 Dec; 44(6):977-980. PubMed ID: 31468576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Point-Counterpoint: Genotype-Guided Warfarin Therapy.
    Lu WJ; Miller NJ
    S D Med; 2017 Feb; 70(2):54-56. PubMed ID: 28810086
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.